Logo

Biomarker Developer LineaGen Closes $5.8M Series A Funding

Dec 20, 2007
NEW YORK (GenomeWeb News) – Salt Lake City-based startup LineaGen closed a $5.8 million round of series A funding, the company said Wednesday.
 
Investors included vSpring Capital, Sanderling Biomedical Ventures, and Mesa Verde Venture Partners.
 
The company plans to use the funds to launch its research program, which will rely on a strategic relationship with the University of Utah to discover and develop biomarkers for major disease areas, including autism, multiple sclerosis, osteoporosis, and chronic obstructive pulmonary disease.
 
Three scientific advisors to the firm are researchers at the University of Utah, and the company plans to use the school’s Utah Population Database, with records for over six million individuals, for its biomarker research.
 
The company also named Dinesh Patel of vSPring, Fred Middleton of Sanderling, and Dan Wood of Mesa Verde to its board of directors.

Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.